Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. - Wikidata - awgldk - TriplyDB

Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome.

Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome.

http://www.wikidata.org/entity/Q44089755

about

Roles of TNF-alpha gene polymorphisms in the occurrence and progress of SARS-Cov infection: a case-control study.The etiology of paraneoplastic autoimmunity.Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.Different role of tumor necrosis factor-α polymorphism in non-Hodgkin lymphomas among Caucasian and Asian populations: a meta-analysis Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes.The major histocompatibility complex conserved extended haplotype 8.1 in AIDS-related non-Hodgkin lymphoma Risk Factors of Non-Hodgkin Lymphoma Tumour necrosis factor-alpha polymorphism as one of the complex inherited factors in pemphigus The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease.Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.Association of tumor necrosis factor genetic polymorphism with chronic atrophic gastritis and gastric adenocarcinoma in Chinese Han population.Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.Tumor necrosis factor-308 polymorphism with the risk and prognosis of non-Hodgkin lymphomas: a meta-analysis study Human leukocyte antigen (HLA) A1-B8-DR3 (8.1) haplotype, tumor necrosis factor (TNF) G-308A, and risk of non-Hodgkin lymphoma.Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era Tumor necrosis factor and cancer, buddies or foes?Survival patterns among lymphoma patients with a family history of lymphoma.Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma.Structure of tumor necrosis factor-alpha haploblocks in European populations.The TNF-α -308 Promoter Gene Polymorphism and Chronic HBV Infection.Inherited variation in immune response genes in follicular lymphoma and diffuse large B-cell lymphoma.Human leukocyte antigens and genetic susceptibility to lymphoma.Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.Tumor necrosis factor (TNF)-α -308G/A (rs1800629) polymorphism distribution in North India and its association with pemphigus: Case-control study and meta-analysis.Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor hematopoietic stem cell transplantation.HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma.A BAFF receptor His159Tyr mutation in Sjögren's syndrome-related lymphoproliferation.TNF-β +252 A>G polymorphism and susceptibility to cancer.The patterns of MHC association in aplastic and non-aplastic paroxysmal nocturnal hemoglobinuria.Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome.Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia.Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab.Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.Tumor necrosis factor alpha promoter polymorphism and the risk of chronic lymphocytic leukemia and myeloma in the Chinese population.Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.Association of hOGG1 Ser326Cys, ITGA2 C807T, TNF-A -308G>A and XPD Lys751Gln polymorphisms with the survival of Malaysian NPC patients.

P2860

Q33321974-98F8380B-10E0-4C2F-90BB-4B9EF7583F7A Q33393705-F255845C-81B0-4584-8073-17D9B321AB37 Q33598099-8B95226B-DD1C-473D-889B-FB293EE59B7B Q33755625-A5B4C899-0063-415E-B82B-370272BE8676 Q34418858-750636ED-0220-4666-AA00-3F3E3EC6098D Q34462958-221F766F-5AE1-4228-9F8D-89112439E60D Q35499320-00C33011-69DF-4A74-9B99-5931D995D414 Q35609374-237D407A-2D4F-4876-9D76-8CAD8BAC272F Q35814374-83A6F6C4-D54D-4C48-A936-7CDD1D233542 Q35839898-3F89E6A0-289F-4A88-A667-32895B080267 Q36213779-A7EE2A0B-36A3-4043-B13C-8509C36B64A9 Q36447972-6CD59459-6817-4B93-A7A0-AF5AD9ABB20F Q36729256-D305ED6F-9BD5-4429-8F32-BEAC2F7F05BE Q36843558-5B8834A9-9388-4A08-9FDA-CF1E8B6EDDC9 Q36915855-ADCCA3CB-C654-4273-829E-F4C3DDEF2505 Q37073092-8F28F14A-5F65-4E3B-8281-3B23A8B0F6FD Q37119385-14124F43-F51D-4793-A5BB-36837EF5A0E9 Q37345560-F1348F29-B276-47FD-A082-A7B8D0E9F96D Q37700889-31E97DE2-459D-4787-A2B4-BAA980C17DA1 Q38058328-BE6D78AB-3F21-43DD-A828-F1A63126D357 Q38516259-6A968573-F338-42DC-8126-295C151C55C1 Q38550267-2FA7D670-5CEB-41B6-94E2-2799ABE6D82E Q38889427-4C551701-9893-4302-8365-B9577FB9467B Q40113952-4A659443-D8DA-418E-9836-C42A2CB58E43 Q40563610-DAD3F9CF-EC7E-4431-A5E2-8EC0B2C91106 Q41050317-AADAE169-BFB0-4C3D-94DD-F5B33822752A Q41652024-C56D4FBE-12FD-4A16-9561-D29BA8D83E6B Q43759426-3408DBC6-5D04-4566-A3DE-90A68BA93B1B Q43803822-7552995F-76A0-42AD-94D1-BB43C5A6BCB0 Q44452652-9B704F63-4446-4737-8138-BF14C38DC02D Q44474899-3D953A18-661C-4800-8D5F-82FA925C1962 Q50873463-258EEBD8-0929-4B8A-BEF6-44727CC2C3D3 Q51339500-90E31098-39A7-4D95-B0EC-F20FCACD6BB7 Q51778567-0BE78EFC-D24A-4B76-BDB3-91A7513A3A54 Q53276851-E64A0339-2C56-4725-9E77-665B4CCF394E Q55249241-D45E4B7F-333F-436F-B71D-A465DBAF6AEF

P2860

Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome.

http://www.wikidata.org/entity/Q44089755

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Human leukocyte antigens class ...... non-Hodgkin lymphoma outcome.

@en

Human leukocyte antigens class ...... non-Hodgkin lymphoma outcome.

@nl

type

label

Human leukocyte antigens class ...... non-Hodgkin lymphoma outcome.

@en

Human leukocyte antigens class ...... non-Hodgkin lymphoma outcome.

@nl

prefLabel

Human leukocyte antigens class ...... non-Hodgkin lymphoma outcome.

@en

Human leukocyte antigens class ...... non-Hodgkin lymphoma outcome.

@nl

P1433

Q44089755-77402E77-CB63-4C9F-ADB2-05612C845769

P1476

Q44089755-FA2245DE-06D0-49B0-8B66-35696FB3D04E

P2093

Q44089755-2398D205-6882-4209-82BC-2FDD215F3A77

Q44089755-609483F3-7DEE-4E8C-A24D-A743EB8A6369

Q44089755-67F2F36E-5655-4974-A515-9311334D290F

Q44089755-6845D6F1-B04A-41A2-82B7-510D78EB3BCA

Q44089755-6946E8CE-30BD-4776-952B-374BC38D1ABD

Q44089755-8E14E754-BE36-4F2C-A9C8-D3B1E0175C47

Q44089755-9A1D6E27-31FD-44C5-9CA4-0830EA8480D3

Q44089755-CAD4A0D4-8BD5-44F5-A01F-0EEF5507B65F

Q44089755-E4F59792-6B55-479A-B8A7-9EE2CCA535F1

Q44089755-ED0980EA-75AB-4BE3-A97E-F88608F6F78A

P304

Q44089755-E338ECCD-2993-4BAE-9FF4-630A125BAEBA

P31

Q44089755-F416EC3B-C1BB-43D1-B73E-5BB9954B2234

P356

Q44089755-5BEDDAD7-9E6C-4B57-A33B-93FE273ABAF1

P407

Q44089755-DA22A7F8-BA3D-4513-A1E1-3F05210D561C

P433

Q44089755-B11333CD-B02D-469D-9B06-5075077276F2

P478

Q44089755-24E68652-CF0D-4544-BFF9-936A285AA640

P50

Q44089755-DD538157-0B93-4C69-ADFD-666C8D7DED33

P577

Q44089755-6667E532-AC46-45C5-8C7A-8220CF79529D

P5875

Q44089755-2B21BA3D-D993-480D-8C01-B646244A3CDB

P698

Q44089755-2723E931-F470-46A9-B424-F8D8147D2BD9

P356

BLOOD-2002-02-0654

P1433

P1476

Human leukocyte antigens class ...... non-Hodgkin lymphoma outcome.

@en

P2093

Bertrand Coiffier

http://www.w3.org/2001/XMLSchema#string

Ewa Kalinka

http://www.w3.org/2001/XMLSchema#string

Ewa Lech-Maranda

http://www.w3.org/2001/XMLSchema#string

Gilles Salles

http://www.w3.org/2001/XMLSchema#string

Grzegorz Woszczek

http://www.w3.org/2001/XMLSchema#string

Jacques Bienvenu

http://www.w3.org/2001/XMLSchema#string

Lucile Baseggio

http://www.w3.org/2001/XMLSchema#string

Maciej Borowiec

http://www.w3.org/2001/XMLSchema#string

Marek Kowalski

http://www.w3.org/2001/XMLSchema#string

Przemyslaw Juszczynski

http://www.w3.org/2001/XMLSchema#string

P304

3037-3040

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2002-02-0654

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Krzysztof Warzocha

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11105913

http://www.w3.org/2001/XMLSchema#string

P698

12351419

http://www.w3.org/2001/XMLSchema#string